Literature DB >> 28342141

Total Tau and Phosphorylated Tau Protein Serum Levels in Patients with Schizophrenia Compared with Controls.

Ömer Faruk Demirel1, Ihsan Cetin2, Şenol Turan3, Nazım Yıldız3, Tarık Sağlam3, Alaattin Duran3.   

Abstract

Tau protein is located in the axons of neurons and in Alzheimer Disease, is abnormally phosphorylated and aggregates into paired helical filaments (neurofibrillary tangles) reflecting the degree of neurofibrillary pathology and neurodegeneration. Although tau and phosphorylated tau (p-Tau) pathology is a hallmark for dementia, few studies were performed in patients of schizophrenia. This preliminary serum study was designed to compare serum total tau and p-Tau levels of schizophrenia patients with healthy controls. The study was included 42 patients diagnosed with schizophrenia and 42 healthy control subjects. Sociodemographic form was applied to both groups and PANSS was applied to patient group. Serum total tau and p-Tau levels were measured by ELISA method. Total tau and p-Tau levels of patients were significantly lower than healthy controls. There was a positive correlation between amount of past electroconvulsive therapies and total tau level. However total tau and p-Tau levels were positively correlated. Our study results showed that serum total tau and p-Tau levels of patients with schizophrenia were significantly lower than healthy controls.

Entities:  

Keywords:  Neurodegeneration; Phosphorylated tau; Schizophrenia; Tau

Mesh:

Substances:

Year:  2017        PMID: 28342141     DOI: 10.1007/s11126-017-9507-x

Source DB:  PubMed          Journal:  Psychiatr Q        ISSN: 0033-2720


  20 in total

Review 1.  Structural brain imaging evidence for multiple pathological processes at different stages of brain development in schizophrenia.

Authors:  Christos Pantelis; Murat Yücel; Stephen J Wood; Dennis Velakoulis; Daqiang Sun; Gregor Berger; Geoff W Stuart; Alison Yung; Lisa Phillips; Patrick D McGorry
Journal:  Schizophr Bull       Date:  2005-07-14       Impact factor: 9.306

2.  Heritability of brain morphology related to schizophrenia: a large-scale automated magnetic resonance imaging segmentation study.

Authors:  Aaron L Goldman; Lukas Pezawas; Venkata S Mattay; Bruce Fischl; Beth A Verchinski; Brad Zoltick; Daniel R Weinberger; Andreas Meyer-Lindenberg
Journal:  Biol Psychiatry       Date:  2007-08-28       Impact factor: 13.382

Review 3.  Heterogeneity of the psychoses: is there a neurodegenerative psychosis?

Authors:  J L Knoll; D L Garver; J E Ramberg; S J Kingsbury; D Croissant; B McDermott
Journal:  Schizophr Bull       Date:  1998       Impact factor: 9.306

Review 4.  Schizophrenia: genes and environment.

Authors:  M Tsuang
Journal:  Biol Psychiatry       Date:  2000-02-01       Impact factor: 13.382

5.  Postmortem studies in schizophrenia.

Authors:  P Powchik; M Davidson; V Haroutunian; S M Gabriel; D P Purohit; D P Perl; P D Harvey; K L Davis
Journal:  Schizophr Bull       Date:  1998       Impact factor: 9.306

6.  Cerebrospinal fluid tau levels in Alzheimer's disease are elevated when compared with vascular dementia but do not correlate with measures of cerebral atrophy.

Authors:  Peter Schönknecht; Johannes Pantel; Tobias Hartmann; Egon Werle; Martin Volkmann; Marco Essig; Michael Amann; Nadja Zanabili; Hubertus Bardenheuer; Aoife Hunt; Johannes Schröder
Journal:  Psychiatry Res       Date:  2003-10-15       Impact factor: 3.222

7.  Progressive brain structural changes mapped as psychosis develops in 'at risk' individuals.

Authors:  Daqiang Sun; Lisa Phillips; Dennis Velakoulis; Alison Yung; Patrick D McGorry; Stephen J Wood; Theo G M van Erp; Paul M Thompson; Arthur W Toga; Tyrone D Cannon; Christos Pantelis
Journal:  Schizophr Res       Date:  2009-01-12       Impact factor: 4.939

Review 8.  Neurodevelopmental and neurodegenerative models of schizophrenia: white matter at the center stage.

Authors:  Peter Kochunov; L Elliot Hong
Journal:  Schizophr Bull       Date:  2014-05-27       Impact factor: 9.306

9.  Cerebrospinal fluid tau protein levels in schizophrenia.

Authors:  Peter Schönknecht; Albrecht Hempel; Aoife Hunt; Ulrich Seidl; Martin Volkmann; Johannes Pantel; Johannes Schröder
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2003-04       Impact factor: 5.270

10.  Total-tau in cerebrospinal fluid of patients with multiple sclerosis decreases in secondary progressive stage of disease and reflects degree of brain atrophy.

Authors:  Jacek Jaworski; Marek Psujek; Marzena Janczarek; Małgorzata Szczerbo-Trojanowska; Halina Bartosik-Psujek
Journal:  Ups J Med Sci       Date:  2012-05-04       Impact factor: 2.384

View more
  1 in total

1.  The study of Tau and phospho Tau protein levels in attention deficit and hyperactivity disorder

Authors:  Hatice Saraçoğlu; Eser Kılıç; Esra Demirci
Journal:  Turk J Med Sci       Date:  2021-08-30       Impact factor: 0.973

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.